Slide 1: 9M 2024 update
9M 2024 update Anna Bertona, Group CEO Thijs Bakker, Group CFO Thursday, October 24, 2024
Slide 2: Agenda
Agenda • Key messages at a glance • Business update • Financial performance • Outlook • Q&A 2 Azelis 9M 2024 update
Slide 3: Disclaimer
Disclaimer • This document may contain statements relevant to Azelis Group NV (the “Company”) and/or its affiliated companies (collectively “Azelis” or the “Azelis Group”) which are not historical facts and are hereby identified as “forward-looking statements”. Such forward-looking statements, inclu
Slide 4: Green shoots are taking root despite persistent volatility
Green shoots are taking root despite persistent volatility Positive organic revenue growth in Q3 reflects gradual recovery with sustained 1 volume growth and prices starting to stabilize in some end-markets. Strong conversion margin maintained as 2 balancing growth recovery and prudent cost manageme
Slide 5: Key developments & business
Key developments & business update Azelis 9M 2024 update
Slide 6: 9M 2024 highlights: Improving trends
• €3.2bn Group revenue, +0.6% y/y (+2.3% in constant FX) supported by M&A contribution and improving organic revenue growth. • +2.8% organic revenue growth in Q3, following declines of 8.1% in Q1 and 0.5% in Q2. 9M 2024 • €784m Gross Profit, driving 59 bp gross profit margin uplift. highlights • €36
Slide 7: Growth drivers
Growth drivers Organic M&A End-markets: Continued volume recovery Five acquisitions completed across our three supported by easing price pressures: regions: • Continued strong HC&IC performance. • Oktrade strengthens our leading position in Personal • Recovery in A&ES across all regions. Care in Tur
Slide 8: Financial performance
Financial performance Azelis 9M 2024 update
Slide 9: Headline P&L 9M 2024
Headline P&L 9M 2024 Azelis Group highlights Reported Reported Constant Q3 2024 Q3 2023 9M 2024 9M 2023 (EUR m) change change currency Life Sciences 661.2 648.5 2.0% 2,009.5 1,965.4 2.2% 4.0% Industrial Chemicals 393.0 389.8 0.8% 1,190.3 1,214.2 -2.0% -0.4% Group Revenue 1,054.2 1,038.3 1.5% 3,199.9
Slide 10: Headline growth 9M 2024
Headline growth 9M 2024 Organic Total Azelis performance F/X M&A growth Organic Total Q3 2024 Q3 2023 9M 2024 9M 2023 growth growth (EUR m) translation contribution growth growth 438.3 434.3 3.2% 0.9% EMEA 1,355.5 1,378.7 -2.5% 3.2% -2.4% -1.7% 392.7 380.7 4.6% 3.2% Americas 1,179.4 1,115.6 0.0% 6.8
Slide 11: Regional financial update
Regional financial update EMEA Americas APAC Adjusted Adjusted Adjusted EBITA 14.2% 13.3% EBITA 13.1% 12.7% EBITA 8.7% 9.9% margin margin margin -1.7% +5.7% € 1.379 € 1.356 € 1.179 -3.0% Revenue Revenue € 1.116 Revenue € 685 € 665 (EUR m) (EUR m) (EUR m) Conversion 53,2% 51,3% Conversion 55,9% 51,0%
Slide 12: Working capital
Working capital Working capital Evolution of NWC* Inventory Receivables Payables EUR million 11.1% 15.3% 13.8% 13.4% 15.3% 16.0% 20,0% NWC/ 1.100 Revenue* 10,0% 900 603 631 700 628 563 0,0% 467 500 -10,0% 268 300 443 445 517 548 -20,0% 376 100 218 -30,0% -100 -235 -369 -463 -434 -455 -488 -40,0% -30
Slide 13: Outlook
Outlook Azelis 9M 2024 update
Slide 14: Sustained recovery
Near-term • Sustained recovery as price stabilization supports volume growth. • Continuation of recovery in industry trends and a return to organic Outlook growth, assuming no new significant market disruptions. • Continue balancing growth recovery and prudent cost management while uncertainty remai
Slide 15: Thank you Q&A
Innovation through formulation